|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | miR-182参与调节胶质母细胞瘤的凋亡、生长和分化(英文)显示文摘Glioblastoma multiforme(GBM)is a lethal,therapy-resistant brain cancer consisting of numerous tumor cell subpopulations,including stem-like glioma-initiating cells(GICs),which contribute to tumor recurrence following initial response to therapy.Here,we identified miR-182 as a regulator of apoptosis,growth,and differentiation programs whose expression level is correlated with GBM patient survival.Repression of Bcl2-like12(Bcl2L12),c-Met,and hypoxia-inducible factor 2α(HIF2A)is of central importance to miR-182 anti-tumor activity,as it results in enhanced therapy susceptibility,decreased GIC sphere size,expansion,and stemness in vitro.To evaluate the tumor-suppressive function of miR-182 in vivo,we synthesized miR-182-based spherical nucleic acids(182-SNAs);i.e.,gold nanoparticles covalently functionalized with mature miR-182 duplexes.Intravenously administered 182-SNAs penetrated the bloodbrain/blood-tumor barriers(BBB/BTB)in orthotopic GBM xenografts and selectively disseminated throughout extravascular glioma parenchyma,causing reduced tumor burden and increased animal survival.Our results indicate that harnessing the anti-tumor activities of miR-182 via safe and robust delivery of 182-SNAs represents a novel strategy for therapeutic intervention in GBM. | Kouri FM Hurley LA Daniel WL Day ES Hua Y Hao L Peng CY Merkel TJ Queisser MA Ritner C Zhang H James CD Sznajder JI Chin L Giljohann DA Kessler JA Peter ME Mirkin CA Stegh AH | 2015 | 中华神经外科疾病研究杂志2015，14，2： | 14 |
| 2 | 钠-葡萄糖共转运蛋白-2抑制剂或胰高血糖素样肽-1受体激动剂治疗成人2型糖尿病:临床实践指南显示文摘临床问题对于存在不同心血管风险及肾脏结局的2型糖尿病患者,在原有生活方式干预和/或其他降糖药物的基础上加用钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂的获益及风险是什么?现行做法几十年来,2型糖尿病的治疗决策都以控制血糖为主导。SGLT-2抑制剂和GLP-1受体激动剂在传统观念中常被用于二甲双胍治疗后血糖仍控制不佳的患者。目前这一现状已经发生了改变,这得益于多项临床研究结果。研究显示SGLT-2抑制剂和GLP-1受体激动剂拥有独立于药物降糖作用之外的对于动脉粥样硬化性心血管病(CVD)和慢性肾脏病(CKD)的获益。建议本指南阐述了针对不同风险分层的成人2型糖尿病患者使用SGLT-2抑制剂或GLP-1受体激动剂的建议。•伴有3种或更少的心血管风险因素且不存在CVD或CKD:不建议启动SGLT-2抑制剂或GLP-1受体激动剂治疗。(推荐等级:弱)•伴有3种以上心血管风险因素且不存在CVD或CKD:建议启动SGLT-2抑制剂治疗,不建议启动GLP-1受体激动剂治疗。(推荐等级:弱)•已经存在CVD或CKD:建议启动SGLT-2抑制剂治疗和GLP-1受体激动剂治疗。(推荐等级:弱)•已经存在CVD和CKD:建议启动SGLT-2抑制剂治疗(推荐等级:强)和GLP-1受体激动剂治疗。(推荐等级:弱)•对于那些想要进一步降低CVD和CKD结局风险的患者:推荐优先启用SGLT-2抑制剂治疗而非GLP-1受体激动剂治疗。(推荐等级:弱)这项指南是如何制订的一个由患者、临床医生和方法学家共同组成的国际小组提出了这些推荐意见。这些推荐意见基于可信度较高的指南的标准,并使用GRADE分级方法进行评估。该小组采用了息者个体化的观点。证据一项关于获益与风险的系统综述和网络meta分析(764项随机对照研究,包括421346例参与者)发现SGLT-2抑制剂和GLP-1受体激动剂可以降低总体死亡率、心肌梗死发生率、终末期肾病或肾衰竭的发生率(中等至高等质量的证据)。在不同的亚组中这些药物对卒中、因心力衰竭所致住院和其他主要不良事件有不同的影响。药物绝对获益的程度因患者个体风险的不同有很大的差异。(例如,对于接受了超过5年药物治疗的1000例患者,在最低风险人群中死亡人数减少了5人,在最高风险人群中死亡人数减少了48人)。一项关于预后的综述确认了14种风险预测模型,其中一种(RECODe)在证据总结中报告了大部分基线风险评估数据,小组利用该模型以支持风险分层的建议。考虑到患者的价值观及个体差异,指南推荐的支撑证据包括一项对已发表论文的系统综述、一项患者焦点小组研究、一项临床问题总结,以及一项指南调查。指南解读我们依据不同的CVD和CKD风险水平,综合考虑获益、风险和其他因素的平衡,以及每一个风险组别的实际问题,来对推荐意见进行分层。本指南强烈建议CVD和CKD患者使用SGLT-2抑制剂治疗,这说明专家组认为其具有显著的获益。而对于其他成人2型糖尿病患者,推荐等级较弱,这说明专家组想要在获益、风险及治疗花费上取得一个更好的平衡。临床医生通过该指南可以使用可靠的风险计算模型,如RECODe,来明确其患者的个体心血管和肾脏疾病风险。医患交互式总结临床证据和制订决策有助于患者知晓治疗选择,包括进行共同决策。2型糖尿病人群(全球患病率不断增长1-2)正面临着不断增加的心血管疾病、肾脏病和其他并发症的风险3。数十年来,2型糖尿病的管理始终以控制血糖及糖化血红蛋白(HbA1c)为治疗目标4-5,但是,最近的高质量随机对照研究已经对这种以血糖为中心的治疗模式发起了挑战。研究结果显示,强化血糖控制未必会降低大血管不良事件,它还可能带来不利影响监管机构现在要求新型糖尿病药物必须证明其具有心血管和肾脏获益才能获得批准。对两类新药--钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂(见框图1)的临床试验结果显示,在现有治疗方案(常规治疗)之上加用这些药物,对死亡、心肌梗死、卒中、心力衰竭和肾脏的结局(如进展为终末期肾病)都有获益8-12。 | Sheyu Li Per Olav Vandvik Lyubov Lytvyn Gordon H Guyatt Suetonia C Palmer Rene Rodriguez-Gutierrez Farid Foroutan Thomas Agoritsas Reed A C Siemieniuk Michael Walsh Lawrie Frere David J Tunnicliffe Evi V Nagler Veena Manja Bjφrn Olav Asvold Vivekanand Jha Mieke Vermandere Karim Gariani Qian Zhao Yan Ren Emma Jane Cartwright Patrick Gee Alan Wickes Linda Fems Robin Wright Ling Li Qiukui Hao Reem A Mustafa 无 郭鹤鸣(译) | 2021 | 英国医学杂志中文版2021，24，9： | 7 |
| 3 | saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription显示文摘 | Victoria Portnoy Szu Hua Sharon Lin Kathy H Li Alma Burlingame Zheng-Hui Hu Hao Li Long-Cheng Li | 2016 | Cell Research2016，26，3： | 6 |
| 4 | Redefining Budd-Chiari syndrome:A systematic review显示文摘AIM:To re-examine whether hepatic vein thrombosis(HVT)(classical Budd-Chiari syndrome)and hepatic vena cava-Budd Chiari syndrome(HVC-BCS)are the same disorder.METHODS:A systematic review of observational studies conducted in adult subjects with primary BCS,hepatic vein outflow tract obstruction,membranous obstruction of the inferior vena cava(IVC),obliterative hepatocavopathy,or HVT during the period of January2000 until February 2015 was conducted using the following databases:Cochrane Library,CINAHL,MEDLINE,Pub Med and Scopus.RESULTS:Of 1299 articles identified,26 were included in this study.Classical BCS is more common in women with a pure hepatic vein obstruction(49%-74%).HVCBCS is more common in men with the obstruction often located in both the inferior vena cava and hepatic veins(14%-84%).Classical BCS presents with acute abdominal pain,ascites,and hepatomegaly.HVC-BCS presents with chronic abdominal pain and abdominalwall varices.Myeloproliferative neoplasms(MPN)are the most common etiology of classical BCS(16%-62%)with the JAK2V617-F mutation found in 26%-52%.In HVCBCS,MPN are found in 4%-5%,and the JAK2V617-F mutation in 2%-5%.Classical BCS responds well to medical management alone and 1st line management of HVC-BCS involves percutaneous recanalization,with few managed with medical management alone.CONCLUSION:Systematic review of recent data suggests that classical BCS and HVC-BCS may be two clinically different disorders that involve the disruption of hepatic venous outflow. | Naomi Shin Young H Kim Hao Xu Hai-Bin Shi Qing-Qiao Zhang Jean Paul Colon Pons Ducksoo Kim Yi Xu Fei-Yun Wu Samuel Han Byung-Boong Lee Lin-Sun Li | 2016 | World Journal of Hepatology2016，8，16： | 6 |
| 5 | Shoot and root traits in drought tolerant maize(Zea mays L.) hybrids显示文摘This study aimed to investigate the differences in shoot and root traits, and water use and water use efficiency(WUE) in drought tolerant(DT) maize(Zea mays L.) hybrids under full and deficit irrigated conditions. A two-year greenhouse study was conducted with four hybrids(one conventional hybrid, 33D53AM, two commercial DT hybrids, P1151 AM, N75H, and an experimental hybrid, Exp HB) grown under two water regimes(I_(100) and I_(50), referring to 100 and 50% of evapotranspiration requirements). Under water stress, the hybids P1151 AM, N75, and Exp HB showed more drought tolerance and had either greater shoot dry weight or less dry weight reduction than the conventional hybrid(33 D53 AM). However, these three hybrids responded to water stress using different mechanisms. Compared with the conventional hybrid, the two commercial DT hybrids(P1151 AM and N75H) had a smaller leaf area, shoot dry weight, and root system per plant. As a result, these hybrids used less water but had a higher WUE compared with the conventional hybrid. In contrast, the experimental hybrid(ExpHB) produced more shoot biomass by silking stage at both irrigation levels than all other hybrids, but it had relatively lower WUE. The hybrids demonstrated different drought response mechanisms that may require different irrigation management strategies. More investigation and validation are needed under field conditions and in different soil types. | ZHAO Jin XUE Qing-wu Kirk E Jessup HOU Xiao-bo HAO Bao-zhen Thomas H Marek XU Wen-wei Steven R Evett Susan A O'Shaughnessy David K Brauer | 2018 | Journal of Integrative Agriculture2018，17，5： | 3 |
| 6 | Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells显示文摘 | Jia Ma Long Cheng Hao Liu Jing Zhang Ying Shi Fanpeng Zeng Lucio Miele Fazlul H Sarkar Jun Xia Zhiwei Wang | 2013 | Current Drug Targets2013，，10： | 2 |
| 7 | Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-Ⅱ (TRACE Ⅱ): rationale and design显示文摘Background and purpose Tenecteplase(TNK)is a promising agent for treatment of acute ischaemic stroke(AIS).We hypothesised that recombinant human TNK tissue-type plasminogen activator(rhTNK-tPA)is non-inferior to rt-PA in achieving excellent functional outcome at 90 days,when administered within 4.5 hours of ischaemic stroke onset.Methods and design Tenecteplase Reperfusion therapy in Acute ischemic Cerebrovascular Events(TRACE)is a phase Ⅲ,multicentre,prospective,randomised,open-label,blinded-end point non-inferiority study.Patients eligible for intravenous thrombolysis therapy are randomised to rhTNK-tPA 0.25 mg/kg(single bolus)to a maximum of 25 mg or rt-PA 0.9 mg/kg(10%bolus+90%infusion/1 hour)to a maximum of 90 mg.Medications considered necessary for the patient’s health may be given at the discretion of the investigator during 90-day follow-up.Study outcomes The primary study outcome is excellent functional outcome defined as modified Rankin Scale(mRS)0–1 at 90 days.Secondary efficacy outcomes include favourable functional outcome defined as mRS≤2 at 90 days,ordinal distribution of mRS and major neurological improvement on the National Institutes of Health Stroke Scale.Safety outcomes are symptomatic intracranial haemorrhage within 36 hours and death from any cause.Discussion There is no completed registration study of TNK in AIS worldwide.TRACE Ⅱ strives to provide evidence for a new drug application for rhTNK-tPA in AIS within 4.5 hours through a well-designed and rigorously executed randomised trial in China. | Shuya Li Bruce C V Campbell Lee H Schwamm Marc Fisher Mark Parsons Hao Li Yuesong Pan Yongjun Wang | 2022 | Stroke & Vascular Neurology2022，7，1： | 2 |
| 8 | 收缩压和舒张压变异性对脑卒中患者血管事件的不同影响显示文摘较高的血压变异性(blood pressure variability,BPV)是心血管病的危险因素。然而,在引发不同的血管事件时,收缩压变异性(systolic blood pressure variability,SBPV)和舒张压变异性(diastolic blood pressure variability,DBPV)是否存在不同作用仍不清楚。本研究旨在探讨SBPV或DBPV对急性缺血性脑卒中(acute ischaemic stroke,IS)或短暂性脑缺血发作(transient ischaemic attack,TIA)患者血管事件的作用是否存在区别。 | 周卫(译) 袁源(摘) 叶鹏(审校) Dai L Cheng A Hao X Xu J Zuo Y Wang A Meng X Li H Wang Y Zhao X Wang Y | 2020 | 中华高血压杂志2020，28，11： | 2 |
| 9 | A molecular roadmap for induced multi-lineage transdifferentiation of fibroblasts by chemical combinations显示文摘 | Xiaoping Han Hao Yu Daosheng Huang Yang Xu Assieh Saadatpour Xia Li Lengmei Wang Jie Yu Luca Pinello Shujing Lai Mengmeng Jiang Xueying Tian Fen Zhang Yanhong Cen Yuko Fujiwara Wei Zhu Bin Zhou Tianhua Zhou Hongwei Ouyang Jianan Wang Guo-Cheng Yuan Shumin Duan Smart H Orkin Guoji Guo | 2017 | Cell Research2017，27，3： | 2 |
| 10 | Response of two-way eccentric building to nonuniform base excitations显示文摘 | | 1998 | Engineering Structures1998，20，8： | 1 |
| 11 | Mechanisms for oil depletion and enrichment on the Shijiutuo uplift, Bohai Bay Basin, China 显示文摘 | HAO F ZHOU X H ZHU Y M | 2009 | AAPG Bulletin2009，93，8： | 1 |
| 12 | Graphene oxide doped polyaniline for supercapacitors显示文摘 | Wang H L Hao Q L Yang X J | 2009 | Electrochemistry Communications2009，11，6： | 1 |
| 13 | A novel pcptide-nucleotide dual vaccine of human telomerase reverse transcfiplase induces a potent cylotoxic T- cell response in vivo显示文摘 | Guo H Hao J Wu C | 2007 | Biochem Biophys Res Commun2007，357，4： | 1 |
| 14 | Microstructure and fatigue characteristics of direct chill cast and electromagnetic cast 2024 Al alloy ingots显示文摘 | Kim S W Hao H | 2003 | Metallurgical and Materials Transactions A: Physical Metallurgy and Materials Science2003，34，7： | 1 |
| 15 | Abnormal organic matter maturation in the Yinggehai Basin, offshore South China Sea:implications for hydrocarbon expulsion and fluid migration from overpressured systems显示文摘 | Hao F Li ST Dong W H | 1998 | Journal of Petroleum Geology1998，21，： | 1 |
| 16 | Increased endoplasmic reticu-lum stress in atherosclerotic plaques associated with acute coronarysyndrome 显示文摘 | Myoishi M Hao H Minamino T | 2007 | Circulation2007，116，11： | 1 |
| 17 | A novel optimiza- tion means of transfer efficiency for resonance coupled wirelesspower transfer显示文摘 | LINLIN T HAO Q XUELIANG H | 2013 | Telkomnika2013，11，5： | 1 |
| 18 | Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis显示文摘 | Zhang H Hao Y Yang J | 2011 | Nature Communications2011，2，： | 1 |
| 19 | Dynamic Response Analysis of Rock Mass with Stochastic Properties Subjected to Explosive Loads显示文摘 | Wu C Q Hao H Ma G W | | 0，，02： | 1 |
| 20 | Novel porous solids for carbon dioxide capture显示文摘 | Hao G P Li WC Lu A H | 2011 | Journal of Materials Chemistry2011，21，18： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员